Company profile
UroGen Pharma Ltd.
NASDAQ:URGNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MITOMYCIN | approved | — | 4 | approved |
| ZALIFRELIMAB | phase2 | — | 3 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05375903 | phase1 | completed | 2022-06-01 | 2026-01-09 | UroGen Pharma Ltd. | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) |
| NCT07725796 | phase1 | not_yet_recruiting | 2026-09-30 | 2029-08-02 | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC |
| NCT03558503 | phase2 | completed | 2018-10-15 | 2020-01-03 | UroGen Pharma Ltd. | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer |
| NCT05243550 | phase3 | active_not_recruiting | 2022-03-01 | 2023-04-26 | UroGen Pharma Ltd. | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer |
| NCT06774131 | phase3 | recruiting | 2025-08-06 | 2027-03-01 | UroGen Pharma Ltd. | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 211728 | NDA | UROGEN PHARMA LTD | ||||
Loading… | ||||||
| NDA 215793 | NDA | UROGEN PHARMA LTD | ||||
Loading… | ||||||